Wyeth

Pfizer Corporation

Janssen Sciences Ireland Uc

The University Court of the University of Aberdeen

Elasmogen Limited

Cornell University

University of Pennsylvania

Beth Israel Deaconess Medical Center, Inc.

Lioudmila Tchistiakova

Xiang-Yang Tan

Kimberly Ann Marquette

Riyez Karim

Davinder Gill

David S Howland

Margaret Maria Zaleska

Frank S Walsh

Pamela Kelley

Seung Poon Kwak

Menelas N Pangalos

Geertruida Machteld Veldman

Angela Widom

Eric M Bennett

Kiran Khandke

Jack Bikker

Samuel Goldman

Debra D Donaldson

Lisa Anne Collins-Racie

Christopher John Corcoran

Edward Roland Lavallie

Caroline Barelle

Puja Sapra

Valerie Calabro

Andrea M Olland

Marion T Kasaian

John Steven

Oleg Kovalenko

John Adam Nowak

Mischa Roland Muller

Nitin Krishnaji Damle

Arthur Kunz

Erwin R Boghaert

Philip Ross Hamann

William Kelley, Legal Representative

John L Knopf

Jose William Saldanha

Lidia Mosyak

Lori J Fitz

James Callaway

Jack Steven Jacobsen

Laura Lin

Ivan Lieberburg

Eric Feyfant

John Francis DiJoseph

Kevin Delos Parris

William James Jonathan Finlay

Michael Grundman

Hans-Peter Gerber

Yijie Gao

Tania Shane

Kenneth G Geles

Bin-Bing Stephen Zhou

Kodangattil R Sreekumar

Amy Sze Pui Tam

Nancy L Wood

Macy X Jin

Bruce Jacobson

Fang Jin

Ronald Black

Lars Ekman

Keith M Gregg

Leslie Sydnor Johnson

Jeffrey A Ledbetter

Paul A Moore

Martha Susan Hayden-Ledbetter

William Brady

Dangshe Ma

James Reasoner Apgar

Nathan Higginson-Scott

Wagner Marcelo Zago

Lewis C Cantley

Edmund Graziani

Lawrence Nathan Tumey

Isaac J Rondon

Ruth E Gimeno

Peter Armstrong Thompson

Madan Katragadda

Chao Bai Huang

Irina Apostolou

Adam Reid Root

Joel Bard

Laird Bloom

L Nathan Tumey

Divya Mathur

Laura Sue Grosmaire

Brooke M Emerling

Chad Michael May

Janet E Paulsen

Manuel J Buttini

Gene G Kinney

Erika L F Holzbaur-Howland

Karen Wallace

Nicholas Weber

Stephen P Soltoff

Cindy M Hodakoski

Brian Gaither Bates

Sreekumar R Kodangattil

Edward Christian Rosfjord

Georgios Poulogiannis

The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

CDCP1 antibodies and antibody drug conjugates

The present invention provides a single domain specific binding molecule having the structureFW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.

Single domain binding molecule

Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.

Humanized antibodies

The present invention provides novel antibodies that specifically bind to CD3 and uses thereof. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Antibodies specific for CD3 and uses thereof

The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C&#x3b3;, C&#x3ba;, and C&#x3bb;) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.

Engineered antibody constant regions for site-specific conjugation and methods and uses therefor

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.

Bispecific antibodies

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8

Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

Anti-5T4 antibodies and uses thereof

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.

Bispecific heterodimeric diabodies and uses thereof

Disclosed herein are anti-IL-13-R&#x3b1;2 antibodies and antibody drug conjugates and methods for preparing and using the same.

Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates

Growing community of inventors

Andover, MA, United States of America

Lioudmila Tchistiakova